You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Carl-Henric Lennart Nilsson

Chief Executive Officer at Kunskapspartner i Lund AB
Overview
Relationships
Paths
Education
Career History
Boards & Committees

Carl-Henric Lennart Nilsson

Chief Executive Officer at Kunskapspartner i Lund AB

Overview

Age
56 (Born 1961)
Notable Companies
Kunskapspartner i Lund AB
Board Seats
7
Number of Relationships
This person is connected to 103 people.

Relationships See Details


Chief Executive Officer & Director at FX International AB

Deputy Director at Endo Medical AB

Professor at Lund University

Associate Professor-Immunotechnology at Lund University

Member, Board of Directors at SenzaGen AB

Director-Sales & Business Development at Novozymes Biopharma Sweden AB

Chief Commercial Officer at Immunovia AB

Partner at Advokatbolaget Wiklund Gustavii Kommanditbolag

Chief Executive Officer at SenzaGen AB

Chief Operating Officer at SenzaGen AB
See 93 more listings with RelSci Professional.

Paths to Carl-Henric Lennart Nilsson

Carl-Henric Lennart Nilsson
You
Connections via Relationship Science
Carl-Henric Lennart Nilsson
Sync your contacts to see how you can connect with Carl-Henric Lennart Nilsson.

Educational Background

 
Lund University is one of northern Europe's oldest and most prestigious universities.

Career History

Chief Executive Officer
Current
Associate Professor
Current
Lund University is one of northern Europe's oldest and most prestigious universities.

Boards & Committees

Corporate Boards ▾
Director
2010 - Current
FX International AB engages in currency trading, which is based on algorithm. Its platform, Genova FX enables to automatically buy and sell currencies through specific tools for electronic foreign exchange trading over computer networks. The company was founded on December 14, 2009 and is headquartered in Helsingborg, Sweden.
Director
Current
Director
Current
SenzaGen AB develops in vitro test methods for prediction of chemical and protein sensitizers. Its offers services for assessment of sensitizers for industry and regulatory purposes, using its proprietary technology called GARD - Genomic Allergen Rapid Detection. Its lead product, the GARD assay for assessment of chemical skin sensitizers, is a method utilizing genomic biomarker signatures for hazard prediction. It serves clients in cosmetic, chemical, pharmaceutical, and food industries. The company was founded by Malin Marie Lindstedt in 2010 and is headquartered in Lund, Sweden.
Director
Current
Director
Current
Director
Prior
Director
Prior

Other Affiliations

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial ➤
Still not convinced? Check out our full listing of features here.